The global narcolepsy market is likely to grow at an 8.2% CAGR between 2017- 2023, according to the recent Market Research Future (MRFR) report. Narcolepsy is a rare condition that is oftentimes under-diagnosed. It is characterized by automatic behaviors, cataplexy, excessive day time sleepiness, sleep paralysis, hallucination, and excessive sleepiness. This disorder is caused by the lack of orexin, a brain chemical that regulates sleep. Puberty and menopause are other factors that can trigger narcolepsy.
Request Sample Copy:
Various factors are adding to the global narcolepsy market share. These factors, as per the new MRFR report, include favorable reimbursement policies, increase in healthcare expenditure, increase in research and development activities for finding a cure for narcolepsy, extensive efforts undertaken by non-government and government organizations to spread awareness about narcolepsy, and growing demand for advanced therapies for sleeping disorders.
The MRFR report provides an inclusive segmental analysis of the global narcolepsy market based on end user, treatment, type, and diagnosis.
By type, the global narcolepsy market is segmented into type 2 narcolepsy, type 1 narcolepsy, and others.
By diagnosis, the global narcolepsy market is segmented into multiple sleep latency test, polysomnogram, and others.
By treatment, the global narcolepsy market is segmented into sodium oxybate, antidepressants, stimulants, and others. The stimulants segment is again segmented into armodafinil, modafinil, and others. The antidepressants segment is again segmented into noradrenergic reuptake inhibitors, selective serotonin, tricyclics, and others. The tricyclics segment is again segmented into clomipramine, desipramine, imipramine, and others. The selective serotonin & noradrenergic segment is again segmented into fluoxetine, venlafaxine, and others.
Based on the region, the global narcolepsy market covers the recent trends and growth opportunities across Europe, the Americas, the Asia Pacific (APAC), and the Middle East and Africa (MEA). Of these, the Americas will have the lions share in the market over the forecast period for a huge patient population, high healthcare expenditure, the presence of key industry players, and a well-developed healthcare sector. Canada and the US are the chief contributors in the region.
The global narcolepsy market in Europe is predicted to have the second-largest share over the forecast period for the presence of developed economies such as Germany, Italy, and France, increasing cases of obesity, huge patient population, and availability of funds for research and development.
The global narcolepsy market in the MEA is predicted to have the smallest share in the market over the forecast period for stringent government policies in the African region and weak economies. The market in the Middle East will have a favorable growth for the huge healthcare expenditure due to the presence of several developed economies such as Qatar, Kuwait, and Saudi Arabia.
Notable players profiled in the global narcolepsy market report include Ligand Pharmaceuticals, Inc. (U.S.), Shionogi Inc. (U.S.), Shire (Republic of Ireland), Novartis AG (Switzerland), Teva Pharmaceutical Industries Ltd. (Israel), Mylan N.V. (US), Graymark Healthcare, Inc. (US), Arena Pharmaceuticals, Inc. (US), BIOPROJET (Paris), and Jazz Pharmaceuticals Plc (Republic of Ireland).
Browse Full Report @
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Market Research Future
+1 646 845 9312